Differential expression of cell adhesion genes: Implications for drug resistance

International Journal of Cancer

Volumn 113, Issue 6, 2005, Pages 861-865

  Stein, Wilfred D ^a,c   Litman, Thomas ^b   Fojo, Tito ^c   Bates, Susan E ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell adhesion; Database mining; Drug resistance; Gene expression; Metastasis; Surveillance, Epidemiology and End Results data

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN; CLATHRIN; COMPLEMENTARY DNA; CONTORTROSTATIN; CYTOTOXIN; DAUNORUBICIN; DISINTEGRIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GALECTIN 3; GUANINE NUCLEOTIDE BINDING PROTEIN; HERMES ANTIGEN; MELPHALAN; MESSENGER RNA; MITOXANTRONE; NETRIN; OBTUSTATIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL X; SALMOSIN; SERINE PROTEINASE; SNAKE VENOM; SPECTRIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VILLIN; VINCA ALKALOID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL MODEL; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL ADHESION; DATA ANALYSIS; DNA REPAIR; DNA SYNTHESIS; EPIDEMIOLOGICAL DATA; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY CANCER; LIVER CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; SERIAL ANALYSIS OF GENE EXPRESSION; SHORT SURVEY; STOMACH CANCER; TESTIS CANCER; TREATMENT OUTCOME; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SURVIVAL ANALYSIS;

EID: 11844264912     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20671     Document Type: Short Survey

References (46)

1. Guden M, Ulutin C, Goktas S. Analyses of 98 seminoma cases: a review article. Int Urol Nephrol 2001;33:529-31.
2. Spermon JR, Witjes JA, Kiemeney LA. Difference in stage and morphology-adjusted survival between young and elderly patients with a testicular germ cell tumor. Urology 2002;60:889-93.
3. DeVita VT, Hellman S, Rosenberg SA. Cancer: principles & practice of oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
4. Stein WD, Litman T, Fojo T, Bates SE. A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res 2004;64:2805-16.
5. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35.
6. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
7. Shain KH, Dalton WS. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 2001;1:69-78.
8. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ. β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002;2:205-16.
9. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res 2002;62:6891-900.
10. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59.
11. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
12. Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary eμ-myc lymphomas in vivo. Blood Cells Mol Dis 2001;27:206-16.
13. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000;6:1029-35.
14. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 1999;83:151-6.
15. Fojo T. p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist Updat 2002;5:209-16.
16. 2/M versus irreversible G, and S arrest. Cell Cycle 2003;2:134-42.
17. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996;56:1834-41.
18. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995;1:305-11.
19. Weaver JR, Wientjes MG, Au JL. Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. Cancer Chemother Pharmacol 1999;44:335-42.
20. Weaver JR, Gan Y, Au JL. Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors. Pharm Res 1998;15:1546-51.
21. Margolis L, Hatfill S, Chuaqui R, Vocke C, Emmert-Buck M, Linehan WM, Duray PH. Long term organ culture of human prostate tissue in a NASA-designed rotating wall bioreactor. J Urol 1999;161:290-7.
22. Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97:8658-63.
23. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-26.
24. Olie RA, Boersma AW, Dekker MC, Nooter K, Looijenga LH, Oosterhuis JW. Apoptosis of human seminoma cells upon disruption of their microenvironment. Br J Cancer 1996;73:1031-6.
25. L. Cancer Res 2001;61:4837-41.
26. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001;29:448-57.
27. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-82.
28. Frankel A, Buckman R, Kerbel RS. Abrogation of Taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997;57:2388-93.
29. WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression. Cancer Res 2000;60:156-63.
30. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF Jr, Hampton GM. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388-93.
31. Bannon LJ, Goldfinger LE, Jones JCR, Green KJ. Desmosomes and hemidesmosomes. In: Beckerle MC, ed. Cell adhesion, 1st ed. Oxford: Oxford University Press, 2001. 324-68.
32. Dzamba BJ, Bolton MA, Desimone DW. The integrin family of cell adhesion molecules. In: Beckerle MC, ed. Cell adhesion, 1st ed. Oxford: Oxford University Press, 2001. 100-54.
33. Peterson L, Burridge K. Focal adhesions and focal complexes. In: Beckerle MC, ed. Cell adhesion, 1st ed. Oxford: Oxford University Press, 2001. 288-323.
34. Duffy MJ, Lynn DJ, Lloyd AT, O'Shea CM. The ADAMs family of proteins: from basic studies to potential clinical applications. Thromb Haemost 2003;89:622-31.
35. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124-38.
36. Christofori G. The implications of angiogenesis on tumor invasiveness. Angogenesis 1998;2:21-3.
37. Marcinkiewicz C, Weinreb PH, Calvete JJ, Kisiel DG, Mousa SA, Tuszynski GP, Lobb RR. Obtustatin: a potent selective inhibitor of α1β1 integrin in vitro and angiogenesis in vivo. Cancer Res 2003;63: 2020-3.
38. Zhou Q, Sherwin RP, Parrish C, Richters V, Groshen SG, Tsao-Wei D, Markland FS. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res Treat 2000;61:249-60.
39. Schmitmeier S, Markland FS, Chen TC. Anti-invasive effect of contortrostatin, a snake venom disintegrin, and TNF-α on malignant glioma cells. Anticancer Res 2000;20:4227-33.
40. Hong SY, Lee H, You WK, Chung KH, Kim DS, Song K. The snake venom disintegrin salmosin induces apoptosis by disassembly of focal adhesions in bovine capillary endothelial cells. Biochem Biophys Res Commun 2003;302:502-8.
41. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002;94:1854-62.
42. Berberat PO, Friess H, Wang L, Zhu Z, Bley T, Frigeri L, Zimmermann A, Buchler MW. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 2001;49:539-49.
43. Miyazaki I, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, Itoh K, Miura S. Increased expression of galectin-3 in primary gastric cancer am the metastatic lymph nodes. Oncol Rep 2002;9:1307-12.
44. Yebra M, Montgomery AM, Diaferia GR, Kaido T, Silletti S, Perez B, Just ML, Hildbrand S, Hurford R, Florkiewicz E, Tessier-Lavigne M, Cirulli V. Recognition of the neural chemoattractant Netrin-1 by integrins α6β4 and α3β1 regulates epithelial cell adhesion and migration. Dev Cell 2003;5:695-707.
45. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-72.
46. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK. SEER cancer statistics review, 1973-1999. Bethesda, MD: National Cancer Institute, 2002.